We then investigated the mechanism of action on PI3K/Akt signaling, rather than MAPK/ERK, as PI3K/AKT signaling is frequently activated as a resistance mechanism in BRAF‐mutant melanoma under BRAF/MEK inhibition.22 Our findings suggest that activation of the Akt pathway by a small molecule activator rescues the effect of magnolol by increasing PI3K/Akt signaling. The gene discussed is MAP2K7; the disease is melanoma.